Background and Purpose-Tobacco cigarette smoking is considered to be a strong risk factor for intracranial aneurysmal rupture. Nicotine is a major biologically active constituent of tobacco products. Nicotine's interactions with vascular cell nicotinic acetylcholine receptors containing α7 subunits (α7*-nAChR) are thought to promote local inflammation and sustained angiogenesis. In this study, using a mouse intracranial aneurysm model, we assessed potential contributions of nicotine exposure and activation of α7*-nAChR to the development of aneurysmal rupture. Methods-Intracranial aneurysms were induced by a combination of deoxycorticosterone-salt induced hypertension and a single-dose elastase injection into cerebrospinal fluid in mice. Results-Exposure to nicotine or an α7*-nAChR-selective agonist significantly increased aneurysm rupture rate.
U nruptured intracranial aneurysms are common, and 1% to 5% of the population may harbor an unruptured intracranial aneurysm. 1 Despite advances in management, subarachnoid hemorrhage from aneurysmal rupture still has high morbidity and mortality. 1 Tobacco contains >7000 different chemicals, including nicotine, and tobacco product use is associated with various cardiovascular and cerebrovascular diseases. 2 Tobacco cigarette smoking is an independent risk factor for intracranial aneurysmal rupture, and the rupture risk in current smokers is 3× higher than that of nonsmokers. 3 Nicotinic acetylcholine receptors (nAChR) are the biological targets of nicotine and mediate natural chemical signaling by acetylcholine. [4] [5] [6] nAChRs are diverse members of the cys loop family of neurotransmitter-gated ion channels. In mammals, nAChRs are composed as pentamers of different combinations of 16, genetically distinct, transmembrane protein subunits.
Each nAChR subtype is defined by its subunit combination, and isoforms of those subtypes are further distinguished based on subunit ratios and arrangements. 7 The accepted nomenclature for nAChR subtypes is based on known or inferred subunit combination and uses an * to indicate that there are known or potential assembly partners in addition to the subunit(s) specified. 8 Each nAChR subtype or isoform has a unique distribution across cell types, organs, and organ regions, and even subcellularly as well as its own pharmacological profile and responsiveness and sensitivity to nicotine and acetylcholine. Vascular cells, including endothelial cells and smooth muscle cells, express the nAChRs containing α7 subunits (α7*-nAChR). 9, 10 Nicotine's interaction with α7*-nAChR on vascular cells promotes inflammation and angiogenesis, 2, 10, 11 biological processes that are important for the development, growth, and rupture of intracranial aneurysms. [12] [13] [14] We hypothesized that nicotine contributes to the
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pathophysiology of intracranial aneurysm through the activation of α7*-nAChR in the vascular wall. Therefore, in this study, using a mouse model of intracranial aneurysm, [13] [14] [15] we studied potential contribution of nicotine exposure to aneurysmal rupture and roles for those effects of α7*-nAChR. Furthermore, using cell type-specific nAChR α7 subunit knockout mice, we defined a cell type involved in nicotine's effects on aneurysmal rupture.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request. Experiments were conducted in accordance with the guidelines approved by the Institutional Animal Care and Use Committee. We obtained α7nAChRflox/flox (α7f/f) mice, 16 α7nAChR knockout (α7nAChR KO) mice, 17 mice expressing Cre recombinase under the control of the myeloid-specific lysosome M (LysM) promoter (LysMCre 18 ), the transgelin (smooth muscle protein 22-α) promoter (SM22Cre 19 ), and the endothelial-specific receptor tyrosine kinase (Tie2) promoter (Tie2Cre   20   ) from Jackson Laboratory (Bar Harbor, Maine). We used LysMCre-, SM22Cre-, and Tie2Cre-negative α7f/f mice as control, and LysMCre-, SM22Cre-, and Tie2Cre-positive α7f/f mice as myeloid-, smooth muscle cell-, and endothelial cell-specific α7nAChR knockout mice. We used 9-week-old male C57BL/6J. To induce aneurysm formation, we combined systemic hypertension and a single injection of elastase (17.5 mU) into the cerebrospinal fluid. [13] [14] [15] 21 To induce systemic hypertension, we used deoxycorticosterone acetate salt-induced hypertension.
Nicotine (Sigma-Aldrich, St. Louis, MO) was dissolved in saline and administrated subcutaneously through Alzet osmotic minipumps (2004, Durect Corporation, Cupertino, CA; 5 mg/kg per day 22 ). α7nAChR agonist (AR-R17779, 5 mg/kg in 5% dimethyl sulfoxide) and α7nAChR antagonist (methyllycaconitine citrate salt, 5 mg/kg in saline) were injected intraperitoneally once a day. 23 Vehicle control groups received saline or 5% dimethyl sulfoxide. All drugs or vehicle were administered from 1 week before elastase injection, and the treatments were continued for 4 weeks.
To detect aneurysmal rupture, 2 blinded observers performed daily neurological examinations as previously described. 14 Mice were euthanized when they developed neurological symptoms (score, 1-5). Asymptomatic mice were euthanized 21 days after aneurysm induction as previously described.
14 The brain samples were perfused with PBS, followed by a gelatin-containing blue dye to visualize cerebral arteries. Aneurysms were defined as a localized outward bulging of the vascular wall, whose diameter was greater than the parent artery diameter. Two observers who were blinded to the treatments and mouse genotypes conducted a daily neurological examination and assessed subarachnoid hemorrhage and aneurysm formations. A detailed Methods section is available in online-only Data Supplement.
Statistical Analysis
We used the Fisher exact test to analyze the incidence of aneurysms (number of mice with any aneurysms [ruptured or unruptured]/total number of mice) and rupture rate (number of mice with ruptured aneurysms/number of mice with any aneurysms). Mice that did not show aneurysm formation were excluded from the calculation of the rupture rate. As an exploratory analysis, the survival analysis was performed using the log-rank test. Levels of mRNA and blood pressure were analyzed by 2-way ANOVA, followed by Tukey-Kramer post hoc test. Statistical significance was accepted at P<0.05. Quantitative results were expressed as mean±SD.
Results
Nicotine Exposure Promotes Aneurysmal Rupture in a Mouse Model of Intracranial Aneurysm
As a first step, we assessed effects of nicotine exposure on the formation and rupture of intracranial aneurysms. There was no significant difference in the overall incidence of aneurysms between the vehicle and nicotine treatment groups (68% versus 76%; n=22 versus n=25; Figure 1A ). However, nicotine treatment significantly increased the aneurysm rupture rate ( Figure 1A ; vehicle versus nicotine: 46% versus 89%; P<0.01). Mice treated with nicotine had significantly worse symptom-free survival compared with vehicle (Kaplan-Meier log-rank P<0.05; Figure 1A) . Figure 1B through 1D shows normal cerebral arteries, an unruptured aneurysm from a mouse that was asymptomatic throughout the experimental period, and a ruptured aneurysm with subarachnoid hemorrhage from a mouse that became symptomatic 8 days after aneurysm induction, respectively. There were hemosiderin deposits on the brain surface along the Circle of Willis because of the blood leakage from the needle track of the elastase injection. There was no significant difference in blood pressure between 2 groups at any time points (Table I in 
Effects of α7*-nAChR Agonist or Antagonist Exposure on the Development of Intracranial Aneurysm Rupture
Because nicotine increased the rate of aneurysmal rupture, we then investigated whether activation of α7*-nAChR mediates nicotine's effects using an α7*-nAChR-selective agonist, AR-R17779. There was no significant difference in the incidence of aneurysm formations between vehicle or α7*-nAChR agonist treatment groups (62% versus 72%; n=16 versus n=18; Figure 2A ). However, the α7*-nAChR agonist significantly increased aneurysmal rupture ( Figure 2A ; 40% versus 92%; P<0.05). Mice treated with the α7*-nAChR agonist had significantly worse symptom-free survival compared with vehicle (Kaplan-Meier log-rank P<0.05; Figure 2A ). There was no significant difference in blood pressure, aneurysm location, or aneurysm size between 2 groups (Tables I  and II in the online-only Data Supplement) .
Next, to test whether α7*-nAChR activation mediates nicotine's promotion of aneurysmal rupture, we compared the rupture rate between mice treated with nicotine alone and those treated with nicotine plus an α7*-nAChR-selective antagonist, methyllycaconitine. There was no significant difference in the incidence of aneurysm formations between nicotine and nicotine+α7*-nAChR-selective antagonist-treated groups (66% versus 77%; n=18 versus n=18; Figure 2B ). However, the α7*-nAChR antagonist effectively abolished nicotine's promotion of aneurysmal rupture ( Figure 2B ; nicotine versus nicotine+antagonist: 100% versus 42%; P<0.01). Mice treated with nicotine plus the α7*-nAChR antagonist had significantly better symptom-free survival compared with those exposed to nicotine alone (Kaplan-Meier log-rank P<0.05; Figure 2B ). α7nAChR antagonist alone did not have any significant effect on the rupture rate (42% versus 38%; n=12 versus 13; P=1.00). There was no significant difference in blood pressure among 3 groups (Table I in 
Aneurysmal Rupture in Global nAChR α7 Subunit Knockout Mice
To further confirm that nicotine exposure promotes aneurysmal rupture through α7*-nAChR, we compared effects of nicotine treatment between nAChR α7 subunit knockout (α7 KO) mice and wild-type littermates.
There was no significant difference in the overall incidence of aneurysms ( Figure 3A ) and blood pressure ( Table I in the online-only Data Supplement) in among 4 groups. However, consistent with results presented in Figure 1 , nicotine treatment significantly increased aneurysmal rupture compared with the vehicle treatment in the wild-type mice ( Figure 3B ; vehicle versus nicotine: 46% versus 84%; P<0.01). More importantly, the effect of nicotine exposure on aneurysmal rupture was abolished in α7 KO mice ( Figure 3B ; wild-type+nicotine versus α7 KO+nicotine: 84% versus 27%; P<0.05). In α7 KO mice, nicotine did not affect the rupture rate ( Figure 3B ; vehicle versus nicotine: 36% versus 27%; P=1.00).
Nicotine Promotes the Expression of Growth Factors and Inflammation in the Cerebral Arteries
Previous studies have shown that the activation of α7*-nAChR in vascular cells promotes sustained angiogenesis and inflammation through the release of angiogenic factors. 2, 10, 11 Therefore, to explore the mechanisms by which nicotine promotes aneurysmal rupture, we used real-time reverse transcription polymerase chain reaction to determine levels of mRNA for angiogenic factors and inflammatory cytokines in cerebral arteries in the vehicle, nicotine, and nicotine+α7*-nAChR antagonist-treated groups.
Expressions of vascular endothelial growth factor (VEGF) and platelet-derived growth factor-B (PDGF-B) in cerebral arteries were significantly higher in the nicotine treatment group than in the vehicle group (n=7 and 6; VEGF: 1.0±0.3 versus 1.6±0.2; PDGF-B: 1.0±0.3 versus 1.6±0.3; all P<0.01; Figure 4A ). Moreover, the presence of an α7*-nAChR antagonist reduced nicotine-mediated elevation of VEGF and PDGF-B (n=7 and 6; VEGF: 1.6±0.2 versus 0.8±0.3; PDGF-B: 1.6±0.3 versus 0.9±0.1; all P<0.01; Figure 4A ). Meanwhile, expression of transforming growth factor-β (TGF-β) was significantly lower in the nicotine group than in the vehicle group (n=7 and 6; TGF-β: 1.0±0.4 versus 0.5±0.1; all P<0.05; Figure 4A ). α7*-nAChR antagonist exposure did not normalize levels of TGF-β mRNA in nicotine-treated mice. There was no difference in fibroblast growth factor-2 or hepatocyte growth factor levels across groups.
mRNA levels of interleukin-6 (IL-6), IL-1β, tumor necrosis factor-α (TNF-α), and matrix metalloproteinase-9 (MMP-9) in cerebral arteries were significantly higher in the nicotine group than in the vehicle group (n=7 and 6; IL-6: 1.0±0.5 versus 2.9±1.8; IL-1β: 1.0±0.7 versus 4.1±1.7; TNF-α: 1.0±0.3 versus 2.9±0.7; MMP-9: 1.0±0.5 versus 2.1±0.4; IL-1b, MMP-9, and TNF-α P<0.01, IL-6 P<0.05; Figure 4B ). Furthermore, addition of an α7*-nAChR antagonist blocked nicotine exposure-induced increases in IL-6, IL-1β, TNF-α, and MMP-9 (n=6; IL-6: 0.5±0.3 versus 2.9±1.8; IL-1β: 1.1±1.1 versus 4.1±1.7; TNF-α: 0.5±0.2 versus 2.9±0.7; MMP-9: 0.8±0.6 versus 2.1±0.4; all P<0.01; Figure 4B ). There was no difference in monocyte chemoattractant protein-1 or nuclear factor κB across groups.
Roles of α7*-nAChR in nicotine-induced inflammation of cerebral arteries were further examined by assessing macrophage infiltration in cerebral arteries. CD68-positive cell density was significantly lower in cerebral arteries from nicotine-treated α7 KO mice (n=6) than in those from nicotinetreated wild-type mice (n=6; CD68: 6.0±2.1 versus 16.5±7.7; P<0.01; Figure 4C ). Figure 4D shows representative staining of cerebral arteries for CD68.
Nicotine Promotes Aneurysmal Rupture via the Activation of VSMC α7*-nAChR
To explore the cell type that mediates deleterious effects of nicotine-induced α7*-nAChR activation, we compared the incidence of aneurysmal ruptures among vascular smooth muscle cell (VSMC)-specific α7 KO mice (α7 Tie2Cre++nicotine: 81% versus 72%; P=1.00). There was no significant difference in the overall incidence of aneurysm formation ( Figure 5 ) or blood pressure (Table I in the onlineonly Data Supplement) between any of 3 cell type-specific α7 KO mice and their corresponding control littermates.
Consistent with results presented in Figure 4A , mRNA levels for VEGF and PDGF-B in cerebral arteries were significantly lower in α7 Figure 6 ). Moreover, expression of fibroblast growth factor-2 was significantly lower in α7 f/f SM22Cre+ mice treated with nicotine than in α7 f/f mice treated with nicotine (n=5; fibroblast growth factor-2: 1.0±0.1 versus 0.4±0.1; P<0.01; Figure 6 ). There was no difference in TGF-β and hepatocyte growth factor expression between these groups.
Discussion
Epidemiological studies have repeatedly shown a positive association between tobacco cigarette smoking and aneurysmal rupture (ie, aneurysmal subarachnoid hemorrhage). However, underlying mechanisms are not well understood nor is the specific role played by nicotine itself as opposed to other constituents of tobacco and of cigarette smoke. Our data indicate that nicotine exposure alone increases rates of aneurysm rupture in a mouse model and that this occurs through activation of VSMC α7*-nAChR. These observations are supported by studies showing that α7*-nAChR-selective antagonism or global knockout of nAChR α7 subunits abolishes the deleterious effect of nicotine exposure on aneurysmal rupture. Moreover, α7 KO specific to VSMCs, but not in inflammatory cells such as macrophages and granulocytes, abolished nicotine's promotion of aneurysmal rupture.
Although stimulation of α7*-nAChR of macrophages and lymphocytes exerts anti-inflammatory effects, 24 vascular cell . C, Effects of α7*-nicotinic acetylcholine receptor (α7*-nAChR) activation by nicotine on the infiltration of macrophages. CD68-positive cell numbers were significantly lower in the collected tissue from nicotine-treated α7 knockout (α7nAChRKO) mice than in nicotine-treated wild-type mice. *P<0.01 vs wild-type+nicotine. D, Representative immunohistochemistry images comparing nicotine-treated α7 KO mice with nicotinetreated wild-type mice. α7 antagonist indicates α7*-nAChR antagonist; FGF, fibroblast growth factor; HGF, hepatocyte growth factor; HPF, high-power field; IL, interleukin; MCP-1, monocyte chemoattractant protein-1; MMP, matrix metalloproteinase; NF, nuclear factor; PDGF, platelet-derived growth factor; TGF, transforming growth factor; TNF, tumor necrosis factor; and VEGF, vascular endothelial growth factor.
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10,26,27 α7*-nAChR mediate nicotine-induced production and release of angiogenic growth factors, including PDGF-BB and VEGF, from vascular cells. 10, 26, 27 PDGF-BB and VEGF, while causing smooth muscle cell proliferation and sustained angiogenesis, promote the release of inflammatory cell attractants into the vascular wall. 27 Expression of VEGF and PDGF-BB in ruptured aneurysms is reported to be higher than those in unruptured aneurysms in humans. 28 Inflammatory cytokines such as TNF-α and IL-1β secreted by inflammatory cells stimulate the release of growth factors from endothelial cells and VSMCs. 29, 30 In our study, nicotine treatment increased expression of VEGF, PDGF-B, and inflammatory cytokines through α7*-nAChR. Both human and animal studies suggest that sustained inflammation and angiogenesis play key roles in the growth and rupture of intracranial aneurysms. 28, 31, 32 Nicotine may promote aneurysm rupture by directly and indirectly causing excessive vascular remodeling and inflammation through the activation of α7*-nAChR.
Interestingly, nicotine reduced mRNA levels of TGF-β in our model, but an α7*-nAChR antagonist did prevent this effect of nicotine. Other nAChR subtypes, such as α9*-or α4β2-nAChR, may regulate TGF-β signaling instead. 33 As TGF-β can protect against pathological vascular remodeling, 34 ,35 α7*-nAChR-independent downregulation of TGF-β by nicotine may further destabilize vascular wall and promote rupture of intracranial aneurysms.
In this study, we did not detect a significant effect of nicotine on the incidence of aneurysm formations. In this model, aneurysmal formations are induced while aneurysmal ruptures occur spontaneously. As the incidence of aneurysm formation in this model was already as high as 70% in the control mice when 17.5 milli units of elastase was used, it may be difficult to reliably detect the further increase in the incidence of aneurysm in the nicotine-treated mice. In addition, it may take a longterm exposure to nicotine to promote the formation of aneurysms. Alternatively, the mechanism for aneurysm formation may be different from the mechanism for aneurysmal rupture. Different doses of nicotine or exposure length may be required for the formation and rupture of intracranial aneurysms.
Different nAChR subtypes can have opposing effects. 10 For example, inhibition or knockdown of α1*-nAChR is reported to reduce aortic plaque development.
2,36 α4β2-nAChR is reported to have anti-inflammatory effects in vitro. 10, 33 Although it is possible that other nAChR subtypes may contribute to different aspects of the pathophysiology of intracranial aneurysms, our data indicate a critical role of α7*-nAChR on VSMCs in mediating nicotine's effects. Further studies using other nAChR subtypespecific knockout mice or inhibitors will elucidate the roles of other nAChRs in the pathophysiology of intracranial aneurysm.
Different doses of nicotine can lead to activation or desensitization of nAChR function and do so at different concentration ranges for different nAChR subtypes. 37 The dose of nicotine used in this study approximates levels previously reported in heavy smokers. 22, 38 This dose has been widely used to study deleterious effects of nicotine in various animal models. 22, 38 However, future studies could investigate whether low doses of nicotine experienced as second-hand smoke affect intracranial aneurysmal rupture.
Finally, as an initial step to study roles of nicotine and α7*-nAChR in the pathophysiology of intracranial aneurysms, we used only male mice in this study. Our previous studies showed that the incidence of aneurysm formation and rupture rates are higher in ovariectomized female mice than male mice and sham-ovariectomized female mice, indicating protective effects of estrogen against the formation and rupture of intracranial aneurysms. 21, 39 The baseline differences in the incidence of aneurysm formations and aneurysmal ruptures among male, nonovariectomized female, and ovariectomized female mice make the inclusion and comparison of these groups would make the experimental design far more complex and highly expansive. Roles of sex differences and sex steroids should be carefully examined in future studies.
Conclusions
This study using a mouse model of intracranial aneurysm shows that nicotine exposure increases aneurysmal rupture through actions on α7*-nAChR on VSMCs and via promotion of sustained angiogenesis and inflammation. α7*-nAChR may serve as a potential therapeutic target for the prevention of intracranial aneurysm rupture. 
